Gifford R R, Voss B V, Schmidtke J R, Ferguson R M
Department of Surgery, Milton S. Hershey Medical Center, Pennsylvania State University, Hershey 17033.
Surgery. 1988 Feb;103(2):184-92.
Cimetidine, a histamine type-2 receptor antagonist, is capable of immunoregulating T cell-mediated proliferative responses in both man and mouse. We present data that show that cell-mediated cytotoxicity (CMC) is also increased by cimetidine in normal and down-regulated murine splenocytes. Timed addition and removal of cimetidine from CMC generation cultures localizes the cimetidine effect to the first 24 hours of the alloantigen sensitization process. Cimetidine partially reverses CMC suppression by suppressor cells generated in vitro in a dose response manner; the result depends on the number of suppressor cells added. Mixed tumor lymphocyte cytotoxicity of splenocytes from syngeneic-tumor-bearing mice is increased by in vivo cimetidine treatment, which results in prolongation of concomitant tumor immunity. These data support the concept that cimetidine may have potential as a clinical immunofacilitator in down-regulated states of immunity.
西咪替丁是一种组胺2型受体拮抗剂，能够对人和小鼠的T细胞介导的增殖反应进行免疫调节。我们提供的数据表明，在正常和下调的小鼠脾细胞中，西咪替丁也会增强细胞介导的细胞毒性（CMC）。在CMC生成培养物中定时添加和去除西咪替丁，将西咪替丁的作用定位在同种异体抗原致敏过程的最初24小时。西咪替丁以剂量反应方式部分逆转体外产生的抑制细胞对CMC的抑制作用；结果取决于添加的抑制细胞数量。体内给予西咪替丁治疗可增强同基因荷瘤小鼠脾细胞的混合肿瘤淋巴细胞细胞毒性，从而延长伴随的肿瘤免疫。这些数据支持这样一种观点，即西咪替丁在免疫下调状态下可能具有作为临床免疫促进剂的潜力。
